Yatai Pharmaceutical released its 2026 interim report, showing a net loss attributable to the parent company of 440,000 yuan in the first half, down 100.4% year on year. Operating revenue was 158 million yuan, up 3.6% year on year. Net profit attributable to the parent company excluding non-recurring items was 1.4 million yuan, compared with a loss of 48.86 million yuan in the same period last year. Second-quarter net profit attributable to the parent company was 2.15 million yuan, down 98.1% year on year. As of the end of the second quarter, total assets stood at 1.192 billion yuan, down 6.9% from the end of the previous year.
Zhejiang Yatai Pharmaceutical Co LtdNet loss attributable to parent of 440,000 yuan in H1, down 100.4% YoY, despite revenue growth.
